WOCKPHARMA2,219.90

Wockhardt Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersBIOCONSYNGENEASTERDMGLANDPPLPHARMACOHANCELALPATHLABNATCOPHARMMcap ₹35,962 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations753.0701.0700.0739.0809.0721.0743.0738.0782.0888.0965.0929.0
Other Income24.08.054.030.09.08.015.020.021.025.045.031.0
Total Income777.0709.0754.0769.0818.0729.0758.0758.0803.0913.01,010.0960.0
Expenses
+ Cost of Materials Consumed179.0160.0144.0150.0182.0121.0159.0168.0159.0170.0177.0233.0
+ Purchases of Stock-in-Trade105.0150.0154.0153.0150.0122.0148.0140.0129.0161.0156.0109.0
+ Changes in Inventories3.0-8.0-4.010.0-35.019.0-47.0-44.0-55.0-14.0-15.0-22.0
+ Employee Benefit Expense166.0152.0157.0160.0161.0164.0166.0171.0186.0181.0187.0203.0
+ Finance Costs76.077.073.073.073.060.048.048.055.060.050.052.0
+ Depreciation & Amortisation55.055.058.054.055.055.053.056.053.065.053.055.0
+ Other Expenses228.0210.0352.0175.0241.0167.0253.0231.0185.0213.0235.0214.0
Total Expenses812.0796.0934.0775.0827.0708.0780.0770.0712.0836.0843.0844.0
EBITDA72.037.0-103.091.0110.0128.064.072.0178.0177.0225.0192.0
EBIT17.0-18.0-161.037.055.073.011.016.0125.0112.0172.0137.0
Profit
PBT before Exceptional Items-35.0-87.0-180.0-6.0-9.021.0-22.0-12.091.077.0167.0116.0
+ Exceptional Items0.00.00.00.00.00.00.0-97.00.0-10.022.00.0
Pretax Income-35.0-87.0-180.0-6.0-9.021.0-22.0-109.091.067.0189.0116.0
+ Current Tax2.03.02.02.03.01.01.04.03.06.05.07.0
+ Deferred Tax36.0-4.0-5.08.04.00.022.0-5.06.00.020.02.0
Tax Expense38.0-1.0-3.010.07.01.023.0-1.09.06.025.09.0
Net Income-73.0-86.0-177.0-16.0-16.020.0-45.0-108.082.061.0164.0107.0
+ Net Income — Continuing Ops-73.0-86.0-177.0-16.0-16.020.0-45.0-108.082.061.0164.0107.0
+ Other Comprehensive Income-20.067.0-40.0-3.089.0-70.056.0148.093.028.0150.014.0
Total Comprehensive Income-93.0-19.0-217.0-19.073.0-50.011.040.0175.089.0314.0121.0
Net Income to Common-77.0-83.0-169.0-14.0-22.014.0-25.0-90.078.059.0166.0106.0
Minority Interest4.0-3.0-8.0-2.06.06.0-20.0-18.04.02.0-2.01.0
Per Share
Basic EPS-5.37-5.75-11.64-0.95-1.470.91-1.57-5.534.813.6110.236.55
Diluted EPS-5.37-5.75-11.64-0.95-1.470.91-1.57-5.534.813.6110.226.55
Other Comprehensive Income — detail
+ Other Comprehensive Income56.0148.093.028.0150.014.0
+ Items NOT to be Reclassified to P&L0.01.0-10.00.00.0-1.0-4.0-0.20.0-1.071.00.0
+ Items to be Reclassified to P&L-20.066.0-30.0-3.089.0-69.060.0148.293.029.079.014.0
Comprehensive Income — Owners of Parent-95.0-27.0-205.0-18.059.0-38.011.049.0163.082.0287.0116.0
Comprehensive Income — Non-controlling Interests2.08.0-12.0-1.014.0-12.00.0-9.012.07.027.05.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-5.37-5.75-11.64-0.95-1.470.91-1.57-5.534.813.6110.236.55
Diluted EPS — Continuing Operations-5.37-5.75-11.64-0.95-1.470.91-1.57-5.534.813.6110.226.55
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit466.0399.0406.0426.0512.0459.0483.0474.0549.0571.0647.0609.0
Gross Margin %61.8956.9258.0057.6563.2963.6665.0164.2370.2064.3067.0565.55
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-35.0-87.0-180.0-6.0-9.021.0-22.0-12.091.077.0167.0116.0
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.0-97.00.0-10.022.00.0
Net Income Adj (tax-effected)-73.0-86.0-177.0-16.0-16.020.0-45.0-11.982.070.1144.9107.0
EPS Adj-5.37-5.75-11.64-0.95-1.470.91-1.57-0.614.814.159.046.55
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.005.005.005.005.005.005.005.005.00
Paid Up Equity Capital72.072.077.077.077.081.081.081.081.081.081.081.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.